MCID: ADR040
MIFTS: 46

Adrenal Gland Pheochromocytoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Adrenal Gland Pheochromocytoma

MalaCards integrated aliases for Adrenal Gland Pheochromocytoma:

Name: Adrenal Gland Pheochromocytoma 12 15 17
Pheochromocytoma 71

Classifications:



External Ids:

Disease Ontology 12 DOID:0050892
UMLS 71 C0031511

Summaries for Adrenal Gland Pheochromocytoma

Disease Ontology : 12 A malignant pheochromocytoma that is characterized by overproduction of adrenaline.

MalaCards based summary : Adrenal Gland Pheochromocytoma, also known as pheochromocytoma, is related to malignant pediatric adrenal gland pheochromocytoma and pheochromocytoma, and has symptoms including tremor, fever and abdominal pain. An important gene associated with Adrenal Gland Pheochromocytoma is PPP1R10 (Protein Phosphatase 1 Regulatory Subunit 10), and among its related pathways/superpathways are Neurotrophic factor-mediated Trk receptor signaling and Microglia Activation During Neuroinflammation: Steady-State Microglia. The drugs Bromocriptine and Nebivolol have been mentioned in the context of this disorder. Affiliated tissues include thyroid, adrenal gland and testes.

Related Diseases for Adrenal Gland Pheochromocytoma

Graphical network of the top 20 diseases related to Adrenal Gland Pheochromocytoma:



Diseases related to Adrenal Gland Pheochromocytoma

Symptoms & Phenotypes for Adrenal Gland Pheochromocytoma

UMLS symptoms related to Adrenal Gland Pheochromocytoma:


tremor, fever, abdominal pain, chest pain, headache

Drugs & Therapeutics for Adrenal Gland Pheochromocytoma

Drugs for Adrenal Gland Pheochromocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 200)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
2
Nebivolol Approved, Investigational Phase 4 152520-56-4, 118457-14-0, 99200-09-6 71301
3
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
4
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
5
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
6
Doxazosin Approved Phase 4 74191-85-8 3157
7
Milnacipran Approved, Investigational Phase 4 92623-85-3 65833
8
Levomilnacipran Approved, Investigational Phase 4 96847-54-0
9 Neurotransmitter Agents Phase 4
10 Adrenergic Agonists Phase 4
11 Adrenergic beta-Agonists Phase 4
12 Adrenergic Agents Phase 4
13 Antihypertensive Agents Phase 4
14 Vasodilator Agents Phase 4
15 Antiparkinson Agents Phase 4
16 Dopamine agonists Phase 4
17 diuretics Phase 4
18 Natriuretic Agents Phase 4
19 Angiotensin II Type 1 Receptor Blockers Phase 4
20 Giapreza Phase 4
21 Sodium Chloride Symporter Inhibitors Phase 4
22 Angiotensin Receptor Antagonists Phase 4
23 Angiotensinogen Phase 4
24 Vasoconstrictor Agents Phase 4
25 Serotonin Uptake Inhibitors Phase 4
26 Analgesics, Non-Narcotic Phase 4
27 Psychotropic Drugs Phase 4
28 Serotonin Agents Phase 4
29 Duloxetine Hydrochloride Phase 4
30 Antidepressive Agents Phase 4
31 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
32 Serotonin Receptor Agonists Phase 4
33
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
34
Tyramine Investigational, Nutraceutical Phase 4 51-67-2 5610
35
Ifosfamide Approved Phase 3 3778-73-2 3690
36
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
37
Lenograstim Approved, Investigational Phase 3 135968-09-1
38
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
39 Calamus Phase 3
40 Antibiotics, Antitubercular Phase 3
41 Anti-Bacterial Agents Phase 3
42
Isophosphamide mustard Phase 3 0
43 Topoisomerase Inhibitors Phase 3
44
Liposomal doxorubicin Phase 3 31703
45
Indinavir Approved Phase 2 150378-17-9 5362440
46
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
47
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
48
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
49
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
50 Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1

Interventional clinical trials:

(show top 50) (show all 111)
# Name Status NCT ID Phase Drugs
1 The Therapeutic Effect of Bromocriptin in Patients With Primary Aldosteronism Unknown status NCT00451672 Phase 4 bromocriptine
2 Comparative Study of the Effects of Telmisartan and Nebivolol on 24-h Ambulatory Blood Pressure and Arterial Stiffness in Patients With Arterial Hypertension Unknown status NCT02057328 Phase 4 TELMISARTAN;NEBIVOLOL
3 Pheochromocytoma Randomised Study Comparing Adrenoreceptor Inhibiting Agents for Preoperative Treatment Completed NCT01379898 Phase 4 Phenoxybenzamine;Doxazosin
4 Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Transperitoneal Laparoscopic Adrenalectomy With a Five-year Follow-up Completed NCT01959711 Phase 4
5 Effectiveness of the Norepinephrine and Serotonin Reuptake Inhibitor Levomilnacipran in Healthy Males Recruiting NCT03249311 Phase 4 Levomilnacipran;Duloxetine;Placebos
6 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Unknown status NCT01373736 Phase 3 123I-meta-iodobenzylguanidine
7 An Open-Label, Multicentre, Phase 3 Scintigraphy Study Assessing 123I-mIBG Uptake in Subjects Being Evaluated for Phaeochromocytoma or Neuroblastoma Completed NCT00126412 Phase 3 123I-mIBG (meta-iodobenzylguanidine)
8 High Dose Indium-111 Pentetreotide Therapy in Somatostatin Receptor Expressing Neuroendocrine Neoplasms. Completed NCT00442533 Phase 2, Phase 3 Indium-111 pentetreotide
9 METASTASECTOMY AND CHEMOTHERAPY FOR LUNG METASTASES FROM SOFT TISSUE SARCOMA: A RANDOMIZED PHASE III STUDY (AN INTERGROUP STUDY WITH THE SCANDINAVIAN SARCOMA GROUP) Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
10 RANDOMISED TRIAL OF ADJUVANT CHEMOTHERAPY WITH HIGH-DOSE DOXORUBICIN, IFOSFAMIDE AND LENOGRASTIM IN HIGH GRADE SOFT TISSUE SARCOMA Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
11 Randomized Controlled Trial of Preoperative Alpha Blockade for Pheochromocytoma Recruiting NCT03176693 Phase 3 Phenoxybenzamine;Doxazosin
12 177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms Unknown status NCT01237457 Phase 2 177Lu-DOTATATE
13 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
14 A Phase II Study of 131I-labeled Metaiodobenzylguanidine (MIBG) for Treatment of Patients With Metastatic or Unresectable Pheochromocytoma and Related Tumors Completed NCT01413503 Phase 2
15 A Phase I Study Evaluating the Maximum Tolerated Dose, Dosimetry, Safety, and Efficacy of Ultratrace Iobenguane I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma Completed NCT00458952 Phase 1, Phase 2 Ultratrace Iobenguane (MIBG) I 131
16 (131)I-Metaiodobenzylguanidine Treatment of Malignant Pheochromocytoma Completed NCT00028106 Phase 2 [131]I-MIBG;6-[18F]Fluorodopamine;[123]I-MIBG
17 Phase II Study of RAD001monotherapy in Patients With Unresectable Pheochromocytoma or Extra-adrenal Paraganglioma or Non-functioning Carcinoid Completed NCT01152827 Phase 2 RAD001
18 A Broad Multi-Histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-Small Cell Lung, Head and Neck, Hepatocellular and Renal Cell Carcinomas and Pheochromocytoma and Thyroid Tumors Completed NCT00923481 Phase 2 Fostamatinib disodium
19 Cisplatin, Doxorubicin and Tamoxifen in the Treatment of Incurable Soft Tissue and Endocrine Malignancies Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
20 A Phase II Study Of Hepatic Arterial Infusion Of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) For Unresectable Primary And Metastatic Cancers Of The Liver Completed NCT00096083 Phase 2 isolated perfusion;melphalan
21 A Phase II Study to Evaluate the Safety and Efficacy of RAD001 Plus Erlotinib in Patients With Well- to Moderately-Differentiated Neuroendocrine Tumors Completed NCT00843531 Phase 2 RAD001;erlotinib
22 A Phase 2 Study of ZD6474 (Vandetanib) in Patients With Von Hippel Lindau Disease and Renal Tumors Completed NCT00566995 Phase 2 ZACTIMA (Vandetanib) (ZD6474)
23 Effect of COMT (Catecholamine-O-methyltransferase) Genetic Polymorphisms on Response to Propranolol Therapy in Temporomandibular Disorder Completed NCT02437383 Phase 2 Propranolol ER;Placebo
24 Open Access Protocol of Targeted Radiotherapy With I-metaiodobenzylguanidine (I-MIBG) in Patients With Resistant Neuroblastoma or Malignant Chromaffin Cell Tumors Recruiting NCT00107289 Phase 2
25 First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma (PPGL) Recruiting NCT01371201 Phase 2 Sunitinib;Placebo
26 Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma Recruiting NCT03839498 Phase 2 Axitinib
27 Phase 2 Study of ONC201 in Neuroendocrine Tumors Recruiting NCT03034200 Phase 2 ONC201
28 Lidocaine Infusion in Functional Endoscopic Sinus Surgery Recruiting NCT03047070 Phase 2 Lidocaine;Normal saline
29 Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma Recruiting NCT03206060 Phase 2 Lu-177-DOTATATE;Ga-68-DOTATATE;F-18-FDG;Amino Acid solution
30 A Phase II Trial of the DNA Methyl Transferase Inhibitor, SGI-110 (Guadecitabine), In Children And Adults With Wild Type GIST, Pheochromocytoma And Paraganglioma Associated With Succinate Dehydrogenase Deficiency And HLRCC-Associated Kidney Cancer Recruiting NCT03165721 Phase 2 SGI-110 (guadecitabine)
31 A Phase II Study to Evaluate the Effects of Cabozantinib in Patients With Unresectable Metastatic Pheochromocytomas and Paragangliomas Recruiting NCT02302833 Phase 2 Cabozantinib S-malate
32 Clinical Study of the Use of Yttrium-90 (90Y) and/or Lutecium-177 (177Lu) DOTATATE (DOTA-0-Tyr3-Octreotate) in the Treatment of Disseminated and / or Symptomatic Tumors With Somatostatin Receptor Overexpression Recruiting NCT04029428 Phase 2 90Y-DOTATATE;(177Lu-DOTAOTyr3)Octreotate;90Y DOTATATE and 177Lu DOTATATE (mix each of 50%)
33 Phase II Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors Recruiting NCT02721732 Phase 2
34 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
35 Phase II Trial of LBlOO, a Protein Phosphatase 2A Inhibitor, in Recurrent Gliomas Recruiting NCT03027388 Phase 2 LB-100
36 Phase II Trial of Lenvatinib in Metastatic or Advanced Pheochromocytoma and Paraganglioma Active, not recruiting NCT03008369 Phase 2 Lenvatinib
37 A Phase 2 Study of Dovitinib in Adults With Advanced Malignant Pheochromocytoma or Paraganglioma Active, not recruiting NCT01635907 Phase 2 Dovitinib
38 A Investigator Initiated Phase II Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma Active, not recruiting NCT00843037 Phase 2 Sunitinib
39 A Phase II Study Evaluating the Efficacy and Safety of Ultratrace Iobenguane I 131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma Active, not recruiting NCT00874614 Phase 2
40 Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma Active, not recruiting NCT01967576 Phase 2 Axitinib (AG-013736)
41 A Phase II Study to Evaluate the Effects of 177Lu-DOTATATE in Patients With Unresectable and Progressive Rare Metastatic Endocrine Carcinomas: Medullary Thyroid Cancer, Parathyroid Carcinoma, Pituitary Carcinoma, and Malignant Pheochromocytoma/Paraganglioma Not yet recruiting NCT04106843 Phase 2 Lutetium Lu 177 Dotatate
42 A Phase 1/2 Trial of a Novel Therapeutic Vaccine (EO2401) in Combination With Immune Check Point Blockade, for Treatment of Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma Not yet recruiting NCT04187404 Phase 1, Phase 2
43 Exploratory Phase II Study of LAnreotide in Metastatic Pheochromocytoma/PARAganglioma (LAMPARA) Not yet recruiting NCT03946527 Phase 2 Lanreotide
44 Phase I/II Trial of Peptide Receptor Radiotherapy (PRRT) With 177Lu-DOTA-tyr3 OCTREOTATE (177Lu-DOTATATE) in Children With Neuroendocrine Tumor, Neuroblastoma, or Pheochromocytoma/Paraganglioma Not yet recruiting NCT03923257 Phase 1, Phase 2 177Lu-DOTA-tyr3-OCTREOTATE
45 Clinical Trial of Sir-Spheres® in Patients With Symptomatic or Progressive Hepatic Metastases From Neuroendocrine Tumors Terminated NCT00466856 Phase 2 octreotide acetate
46 A Phase 2 Study of Pazopanib (GW786034) in Patients With Advanced and Progressive Malignant Pheochromocytoma or Paraganglioma Terminated NCT01340794 Phase 2 Pazopanib Hydrochloride
47 Treatment Targets for Chronic Hypertension in Pregnancy Withdrawn NCT00194974 Phase 1, Phase 2 methyldopa;labetalol;nifedipine;clonidine
48 Parenteral Phenoxybenzamine During Congenital Heart Disease Surgery Withdrawn NCT00770705 Phase 2 Phenoxybenzamine
49 Phase 1 Study Evaluating the Safety, Distribution, Metabolism, and Radiation Dosimetry of ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma or Metastatic Carcinoid Completed NCT00339131 Phase 1 Ultratrace iobenguane I 131
50 A Phase I, Open Label, Maximum Tolerated Dose-Finding Study to Evaluate the Safety and Tolerability of 90Y-DOTA-tyr3-Octreotide Administered by Intravenous Infusion to Children With Refractory Somatostatin-Receptor Positive Tumors Completed NCT00049023 Phase 1

Search NIH Clinical Center for Adrenal Gland Pheochromocytoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Metyrosine
Phenoxybenzamine
Phenoxybenzamine Hydrochloride
Propranolol
Propranolol Hydrochloride

Genetic Tests for Adrenal Gland Pheochromocytoma

Anatomical Context for Adrenal Gland Pheochromocytoma

MalaCards organs/tissues related to Adrenal Gland Pheochromocytoma:

40
Thyroid, Adrenal Gland, Testes, Heart, Brain, Pituitary, Bone

Publications for Adrenal Gland Pheochromocytoma

Articles related to Adrenal Gland Pheochromocytoma:

(show top 50) (show all 15274)
# Title Authors PMID Year
1
Metastatic pheochromocytoma to the pancreas diagnosed by endoscopic ultrasound-guided fine needle aspiration: A case report and review of literature. 61
31639290 2020
2
Multifocal Urinary Bladder Paragangliomas With Negative 68Ga-DOTATATE Uptake and Positive 123I-MIBG Uptake. 61
31714281 2020
3
Long noncoding RNA MEG3 silencing protects against hypoxia-induced pheochromocytoma-12 cell injury through inhibition of TIMP2 promoter methylation. 61
31392726 2020
4
Concurrent heterozygous Von-Hippel-Lindau and transmembrane-protein-127 gene mutation causing an erythropoietin-secreting pheochromocytoma in a normotensive patient with severe erythrocytosis. 61
31568062 2020
5
Ectopic Cushing's syndrome associated with a pheochromocytoma in a dog: a case report. 61
32014021 2020
6
Clinical factors affecting spot urine fractionated metanephrines in patients suspected pheochromocytoma/paraganglioma. 61
32020083 2020
7
Response to Letter to the Editor: "Pheochromocytoma Characteristics and Behavior Differ Depending on Method of Discovery". 61
31624835 2020
8
Letter to the Editor: "Pheochromocytoma Characteristics and Behavior Differ Depending on Method of Discovery". 61
31624836 2020
9
Clinical and Biochemical Features of Pheochromocytoma Characteristic of Von Hippel-Lindau Syndrome. 61
31773218 2020
10
A pheochromocytoma on steroids. 61
31749058 2020
11
Adrenalectomy for non-neuroblastic pathology in children. 61
31691026 2020
12
Synthesis of Dithiolethiones and Identification of Potential Neuroprotective Agents via Activation of Nrf2-Driven Antioxidant Enzymes. 61
31986030 2020
13
LONP1 induction by SRT1720 attenuates mitochondrial dysfunction against high glucose induced neurotoxicity in PC12 cells. 61
31639451 2020
14
Sustained GRK2-dependent CREB activation is essential for α2-adrenergic receptor-induced PC12 neuronal differentiation. 61
31678682 2020
15
Modulation activity of heat-treated and untreated lactoferrin on the TLR-4 pathway in anoxia cell model and cerebral ischemia reperfusion mouse model. 61
31837800 2020
16
Comparison of the retroperitoneal versus Transperitoneal laparoscopic Adrenalectomy perioperative outcomes and safety for Pheochromocytoma: a meta-analysis. 61
31931809 2020
17
The determination of real fluid requirements in laparoscopic resection of pheochromocytoma using minimally invasive hemodynamic monitoring: a prospectively designed trial. 61
30976898 2020
18
Carbonic anhydrase 9 immunohistochemistry as a tool to predict or validate germline and somatic VHL mutations in pheochromocytoma and paraganglioma-a retrospective and prospective study. 61
31383958 2020
19
Very high rate of false positive biochemical results when screening for pheochromocytoma in a large, undifferentiated population with variable indications for testing. 61
31978379 2020
20
Bleeding angiomyolipoma mimiking a ruptured adrenal tumour. 61
31641611 2020
21
Development and validation of a clinical model to predict intraoperative hemodynamic instability in patients with pheochromocytomas surgery. 61
31597814 2020
22
Malignant pheochromocytoma and paraganglioma: management options. 61
31599769 2020
23
Adrenocortical carcinoma masquerading as pheochromocytoma: a histopathologic dilemma. 61
31917677 2020
24
A surface-enhanced Raman scattering-based probe method for detecting chromogranin A in adrenal tumors. 61
31983270 2020
25
Targeting NRF2-Governed Glutathione Synthesis for SDHB-Mutated Pheochromocytoma and Paraganglioma. 61
31979226 2020
26
Open surgery for pheochromocytoma: Current indications and outcomes from a retrospective cohort. 61
31983822 2020
27
Successful treatment of giant pheochromocytoma-induced Takotsubo syndrome with consequent adrenalectomy conversion. 61
31916544 2020
28
Pheochromocytoma and Paraganglioma Patients with Poor Survival Often Show Brown Adipose Tissue Activation. 61
31903484 2020
29
Reverse Takotsubo Pattern in the Setting of Undiagnosed Pheochromocytoma and Pulmonary Embolism: A Rare Presentation. 61
31949122 2020
30
Another Role for Angiotensin II?: Vasopressin-Refractory Shock After Pheochromocytoma Resection: A Case Report. 61
31770125 2020
31
First case report of pheochromocytoma and IgG4-related disease. Cause or coincidence? 61
31928980 2020
32
Incidental giant cystic pheochromocytoma: a case report and review of the literature. 61
31931648 2020
33
Pheochromocytoma and paraganglioma: An emerging cause of secondary osteoporosis. 61
31940499 2020
34
Long-term Clinicopathological Features of a Family with Multiple Endocrine Neoplasia Type 2A Caused by C634R RET Gene Mutation. 61
31949369 2020
35
Erigeron annuus Protects PC12 Neuronal Cells from Oxidative Stress Induced by ROS-Mediated Apoptosis. 61
31998396 2020
36
Molecular pathogenesis of tumorigenesis caused by succinate dehydrogenase defect. 61
31810635 2020
37
Direct Activation of TRPC3 Channels by the Antimalarial Agent Artemisinin. 61
31947602 2020
38
Isolated left adrenal medullary hyperplasia. 61
31933700 2020
39
Carvacrol Protects Against 6-Hydroxydopamine-Induced Neurotoxicity in In Vivo and In Vitro Models of Parkinson's Disease. 61
31364033 2020
40
MiR-429/200a/200b negatively regulate Notch1 signaling pathway to suppress CoCl2-induced apoptosis in PC12 cells. 61
32004541 2020
41
Gold-Nanoparticle-Mediated Depolarization of Membrane Potential Is Dependent on Concentration and Tethering Distance from the Plasma Membrane. 61
31894966 2020
42
The Dephosphorylation of p70S6 (Thr389) Kinase as a Marker of L-Glutamate-Induced Excitotoxicity Related to Diabetes Disturbances-an Unconventional In Vitro Model. 61
31900899 2020
43
Adrenal masses in children: Imaging, surgical treatment and outcome. 61
30962018 2020
44
Germline mutations in the new E1' cryptic exon of the VHL gene in patients with tumours of von Hippel-Lindau disease spectrum or with paraganglioma. 61
31996412 2020
45
Cyanidin-3-O-Glucoside Protects PC12 Cells Against Neuronal Apoptosis Mediated by LPS-Stimulated BV2 Microglial Activation. 61
31485933 2020
46
RyRs mediate lead-induced neurodegenerative disorders through calcium signaling pathways. 61
31710906 2020
47
Current role of open surgery in adrenal tumors. 61
32038016 2020
48
Favorable outcome of pheochromocytoma in a dog with atypical Cushing's syndrome and diabetes mellitus following medical treatment: a case report. 61
31900158 2020
49
Clinical implications of the oncometabolite succinate in SDHx-mutation carriers. 61
30977114 2020
50
'Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: A systematic review and meta-analysis'. 61
31569282 2019

Variations for Adrenal Gland Pheochromocytoma

Cosmic variations for Adrenal Gland Pheochromocytoma:

9 (show top 50) (show all 190)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM88294223 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.499C>T p.R167W 3:10149822-10149822 6
2 COSM88301868 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.389T>G p.V130G 3:10146562-10146562 6
3 COSM88294143 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.260T>C p.V87A 3:10142107-10142107 6
4 COSM88293303 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.475A>G p.K159E 3:10149798-10149798 6
5 COSM88288959 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.482G>A p.R161Q 3:10149805-10149805 6
6 COSM88296074 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.250G>C p.V84L 3:10142097-10142097 6
7 COSM88292246 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.227T>A p.F76Y 3:10142074-10142074 6
8 COSM88292324 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.496G>T p.V166F 3:10149819-10149819 6
9 COSM88305342 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.492G>T p.Q164H 3:10149815-10149815 6
10 COSM88292236 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.491A>G p.Q164R 3:10149814-10149814 6
11 COSM88306166 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.593T>C p.L198P 3:10149916-10149916 6
12 COSM88299307 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.250G>A p.V84M 3:10142097-10142097 6
13 COSM88205586 TP53 adrenal gland,adrenal gland,pheochromocytoma,NS c.349G>C p.G117R 17:7676020-7676020 6
14 COSM87898351 TP53 adrenal gland,adrenal gland,pheochromocytoma,NS c.743G>A p.R248Q 17:7674220-7674220 6
15 COSM87955161 TP53 adrenal gland,adrenal gland,pheochromocytoma,NS c.305C>T p.T102I 17:7676064-7676064 6
16 COSM92347003 RET adrenal gland,adrenal gland,pheochromocytoma,NS c.2753T>C p.M918T 10:43121968-43121968 6
17 COSM92347226 RET adrenal gland,adrenal gland,pheochromocytoma,NS c.1900T>C p.C634R 10:43114500-43114500 6
18 COSM93656552 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.1885G>A p.G629R 17:31225134-31225134 6
19 COSM93692982 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.5665G>T p.E1889* 17:31330351-31330351 6
20 COSM93650970 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.1466A>G p.Y489C 17:31214524-31214524 6
21 COSM93657331 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.4558C>T p.Q1520* 17:31260496-31260496 6
22 COSM93646872 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.3721C>T p.R1241* 17:31235623-31235623 6
23 COSM93662933 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.7582C>T p.Q2528* 17:31352381-31352381 6
24 COSM93654948 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.7646C>G p.S2549* 17:31356490-31356490 6
25 COSM93650764 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.7300C>T p.Q2434* 17:31349230-31349230 6
26 COSM93652933 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.205-1G>C p.? 17:31159009-31159009 6
27 COSM93668028 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.1722-1G>A p.? 17:31223443-31223443 6
28 COSM93647950 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.1721+3A>T p.? 17:31221932-31221932 6
29 COSM93688082 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.6855C>A p.Y2285* 17:31338739-31338739 6
30 COSM93680586 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.226G>T p.E76* 17:31159031-31159031 6
31 COSM93687360 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.3158C>A p.S1053* 17:31230886-31230886 6
32 COSM93653832 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.2409+1G>A p.? 17:31227607-31227607 6
33 COSM88844097 MET adrenal gland,adrenal gland,pheochromocytoma,NS c.3029C>T p.T1010I 7:116771936-116771936 6
34 COSM88849124 MET adrenal gland,adrenal gland,pheochromocytoma,NS c.607T>A p.S203T 7:116699691-116699691 6
35 COSM88850455 MET adrenal gland,adrenal gland,pheochromocytoma,NS c.352A>T p.M118L 7:116699436-116699436 6
36 COSM87668405 KMT2D adrenal gland,adrenal gland,pheochromocytoma,NS c.8764C>T p.R2922W 12:49038592-49038592 6
37 COSM87676802 KMT2D adrenal gland,adrenal gland,pheochromocytoma,NS c.15666C>A p.N5222K 12:49026300-49026300 6
38 COSM87654373 KMT2D adrenal gland,adrenal gland,pheochromocytoma,NS c.15668A>G p.N5223S 12:49026298-49026298 6
39 COSM87697808 KMT2D adrenal gland,adrenal gland,pheochromocytoma,NS c.8203G>A p.G2735S 12:49039461-49039461 6
40 COSM87681614 KMT2D adrenal gland,adrenal gland,pheochromocytoma,NS c.7829T>C p.L2610P 12:49039941-49039941 6
41 COSM87715792 KMT2D adrenal gland,adrenal gland,pheochromocytoma,NS c.12664C>G p.L4222V 12:49032041-49032041 6
42 COSM87718583 KMT2D adrenal gland,adrenal gland,pheochromocytoma,NS c.7607T>C p.F2536S 12:49040163-49040163 6
43 COSM112988851 HRAS adrenal gland,adrenal gland,pheochromocytoma,NS c.182A>G p.Q61R 11:533874-533874 6
44 COSM112988925 HRAS adrenal gland,adrenal gland,pheochromocytoma,NS c.181C>A p.Q61K 11:533875-533875 6
45 COSM112988832 HRAS adrenal gland,adrenal gland,pheochromocytoma,NS c.37G>C p.G13R 11:534286-534286 6
46 COSM95516578 H3-3A adrenal gland,adrenal gland,pheochromocytoma,NS c.103G>T p.G35W 1:226064454-226064454 6
47 COSM93760866 GNAS adrenal gland,adrenal gland,pheochromocytoma,NS c.2530C>T p.R844C 20:58909365-58909365 6
48 COSM107493928 FGFR1 adrenal gland,adrenal gland,pheochromocytoma,NS c.1731C>A p.N577K 8:38417331-38417331 6
49 COSM86761750 EPAS1 adrenal gland,adrenal gland,pheochromocytoma,NS c.1104G>A p.M368I 2:46376608-46376608 6
50 COSM86762542 EPAS1 adrenal gland,adrenal gland,pheochromocytoma,NS c.1588G>C p.A530P 2:46380260-46380260 6

Expression for Adrenal Gland Pheochromocytoma

Search GEO for disease gene expression data for Adrenal Gland Pheochromocytoma.

Pathways for Adrenal Gland Pheochromocytoma

Pathways related to Adrenal Gland Pheochromocytoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
10.74 NGF BDNF
2 10.28 NGF BDNF

GO Terms for Adrenal Gland Pheochromocytoma

Biological processes related to Adrenal Gland Pheochromocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of neuron differentiation GO:0045664 9.37 NGF BDNF
2 neurotrophin TRK receptor signaling pathway GO:0048011 9.32 NGF BDNF
3 nerve development GO:0021675 9.26 NGF BDNF
4 nerve growth factor signaling pathway GO:0038180 9.16 NGF BDNF
5 positive regulation of collateral sprouting GO:0048672 8.96 NGF BDNF
6 peripheral nervous system development GO:0007422 8.8 SERPINI1 NGF BDNF

Sources for Adrenal Gland Pheochromocytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....